Eli Lilly

News

Teva slumps after Express Scripts funds migraine rivals in U...

A major prescription benefit manager in the US will not reimburse Teva’s preventative migraine drug Ajovy (fremanezumab), in an effort to cut costs.

News

Lilly unveils promising data from dual-action diabetes drug

Eli Lilly’s investigational diabetes drug has shown early promise as a possible aid to overcoming obesity in trial results announced this week.

News

Lilly's breast cancer drug Verzenio approved in EU

Eli Lilly’s Verzenio breast cancer drug has been approved in Europe, as the pharma prepares to compete with established rivals from Pfizer and Novartis.

News

Novo to market 'connected' insulin pens next year

Novo Nordisk is to launch “connected” insulin pens, responding for demands from patients for devices able to communicate with glucose monitoring systems and glucose meters.

News

Lilly pushes into migraine market as Emgality approved in US

The FDA has approved Eli Lilly’s Emgality (galcanezumab) for migraine prevention in adults, the third in a group of new class of drugs for the condition.

News

FDA approves Teva's migraine drug, decision due on Lilly's r...

The FDA has finally approved Teva’s potential blockbuster migraine drug Ajovy after months of delays due to concerns about the manufacturing plant operated by the company’s partner, Celltri

Teva slumps after Express Scripts funds migraine rivals in U...

Lilly unveils promising data from dual-action diabetes drug

Lilly's breast cancer drug Verzenio approved in EU

Novo to market 'connected' insulin pens next year

Lilly pushes into migraine market as Emgality approved in US

FDA approves Teva's migraine drug, decision due on Lilly's r...

BioMarin ends year with $4.8bn play for Amicus

How to meet your physicians where they are online

Eli Lilly

Editor's Picks